Ann: Quarterly Activities Report and Appendix 4C, page-7

Quarterly Activities Report For the period ending 31 December 2021

ResAppDx now live on Alodokter and Doctors on Demand’s telehealth platforms

Janssen Pharmaceutica NV to use ResAppDx technology in a respiratory syncytial virus (RSV) clinical trial

Emerging markets distribution agreement signed with Sanrai International § Partnership with Carepath Technologies GmbH for remote monitoring and management of COPD patients

Completed recruitment in clinical studies in India and the United States to develop an instant smartphone-based COVID-19 screening test

Customer receipts for the quarter increased to $124,000 (Q1: $7,000)